AVEO Pharmaceuticals Inc – AVEO

April 1, 2018 – June 30, 2018 all-day

AVEO Pharmaceuticals Inc – AVEO

Top-line data due 2Q 2018 for TIVO-3 – tivozanib
Third line treatment of patients with renal cell cancer.

Phase 3 completion of enrollment noted June 20, 2017. Futility analysis released October 6, 2017 – trial to continue as planned.
Top-line data due 2Q 2018.

[stockdio-historical-chart symbol=”AVEO” stockExchange=”NYSE” displayPrices=”candlestick” days=”90″ width=”580″ height=”380″ motif=”financial” palette=”financial-light”]


Author: ZitroStocks

Welcome to ZitroStocks, hope you enjoy your visit. You are welcome to ask questions and participate in discussions.

One thought on “AVEO Pharmaceuticals Inc – AVEO”

Leave a Reply

Your email address will not be published. Required fields are marked *